Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

Cancer Science
Ken OhmachiJapanese Bendamustine Lymphoma Study Group

Abstract

Bendamustine is a unique cytotoxic agent that has demonstrated efficacy in the treatment of indolent B-cell non-Hodgkin lymphomas (B-NHLs). In this multicenter phase II trial, the efficacy and safety of bendamustine were evaluated in Japanese patients with relapsed or refractory indolent B-NHL or mantle-cell lymphoma (MCL). Patients received bendamustine (120 mg/m(2) ) on days 1-2 of a 21-day cycle, for up to six cycles. The primary endpoint was the overall response rate (ORR) as assessed by an extramural committee according to International Workshop Response Criteria (IWRC). Secondary endpoints included complete response (CR) rate, ORR according to Revised Response Criteria (revised RC), progression-free survival (PFS), and safety. Fifty-eight patients with indolent B-NHL and 11 with MCL were enrolled. By IWRC, bendamustine produced an ORR of 91% (95% confidence interval [CI], 82-97%; 90% and 100% in patients with indolent B-NHL and MCL, respectively), with a CR rate of 67% (95% CI, 54-78%). ORR and CR rates according to revised RC were 93% (95% CI, 84-98%) and 57% (95% CI, 44-68%), respectively. After a median follow-up of 12.6 months, median PFS had not been reached. Estimated PFS rates at 1 year were 70% and 90% among indol...Continue Reading

References

Mar 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S A Rosenberg
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S CzuczmanC Varns
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
May 6, 2004·Blood·Philippe Solal-CélignyEmili Montserrat
Oct 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Myron S CzuczmanAntonio J Grillo-López
Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
Aug 12, 2005·Current Opinion in Oncology·Michael E Williams, John J Densmore
Oct 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard I FisherThomas P Miller
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Jan 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lorenzo M LeoniChristina C Niemeyer
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonathan W FriedbergBruce D Cheson
Feb 7, 2008·Pathology International·Ryosuke AokiKoichi Ohshima
Jul 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K Sue RobinsonBruce D Cheson
Apr 27, 2010·Australian Dental Journal·UNKNOWN Australian Research Centre for Population Oral Health, The University of Adelaide, South Australia

❮ Previous
Next ❯

Citations

Apr 18, 2013·Annals of Hematology·Francesco ZajaRenato Fanin
Jul 13, 2011·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Yusuke FurukawaYasuhiko Kano
Jun 23, 2011·Clinical Medicine Insights. Oncology·Nishant Tageja
Jun 20, 2014·Journal of Clinical and Experimental Hematopathology : JCEH·Koji Izutsu
Apr 27, 2012·Advances in Hematology·Kenneth A FoonPier L Zinzani
Jun 1, 2011·Leukemia & Lymphoma·Stephen E SpurgeonElliot M Epner
Sep 14, 2012·Expert Opinion on Drug Metabolism & Toxicology·Anna Korycka-Wołowiec, Tadeusz Robak
Nov 22, 2015·International Journal of Hematology·Kensei TobinaiSatoko Takahara
Jul 26, 2011·Seminars in Hematology·Stéphanie HarelOlivier Hermine
Jul 24, 2014·Clinical Lymphoma, Myeloma & Leukemia·Annete NjueFarrukh Awan
Apr 2, 2015·Cancer Chemotherapy and Pharmacology·Mona DarwishJames P Chovan
May 8, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ken OhmachiMichinori Ogura
Mar 28, 2012·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Toshihisa NakashimaTakayoshi Kiba
Mar 16, 2018·Expert Review of Hematology·Thomas Erblich, Silvia Montoto
Nov 28, 2017·Leukemia & Lymphoma·Martin DreylingPier Luigi Zinzani
Jan 17, 2013·Drugs in R&D·Anne-Charlotte DubbelmanJan H M Schellens
Jul 1, 2014·British Journal of Haematology·Yiming ChenJorge Romaguera
Feb 6, 2017·International Journal of Hematology·Yoshiaki OgawaUNKNOWN Japanese Bendamustine CLL Study Group
Aug 18, 2020·Biological & Pharmaceutical Bulletin·Mayako UchidaTsutomu Nakamura
Oct 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mauricio BurottoRobert J Kreitman
Mar 21, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jacob D SoumeraiJohn F Gerecitano
Jun 16, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Changchun DengOwen A O'Connor

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.